Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2020-04-24 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于2019年年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from the company regarding the 2019 annual profit distribution plan, including dividend per share, total dividend amount, and the approval process by the board of directors. It details the dividend payout and mentions that the plan will be submitted to the shareholders' meeting for approval. The document is short (1350 characters) and focuses on dividend distribution details rather than the full annual report or financial statements. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and related details to shareholders.
2020-04-24 Chinese
第十届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Mayinglong Pharmaceutical Group Co., Ltd. It details the approval of several reports including the 2019 Supervisory Board Work Report, the 2019 Annual Report and its summary, the 2019 Internal Control Evaluation Report, and the 2020 Q1 Report. It also mentions approval of an accounting policy change. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the reports themselves. The document length is short (1473 characters) and it serves as a meeting resolution announcement rather than the full annual or quarterly report. Therefore, it fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals, not the full reports or financial statements themselves.
2020-04-24 Chinese
第十届董事会第六次会议决议公告
Annual Report Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 6th meeting of the 10th Board of Directors of 马应龙药业集团股份有限公司, held on April 23, 2020. It includes approval of various reports such as the 2019 General Manager Work Report, 2019 Board Work Report, 2019 Independent Directors Report, 2019 Audit Committee Report, 2019 Financial Final Accounts Report, 2019 Profit Distribution Plan, 2019 Annual Report and Summary, 2019 Internal Control Evaluation Report, 2019 Social Responsibility Report, and the 2020 Q1 Report. It also covers decisions on audit firm appointment, accounting policy changes, loan guarantees for subsidiaries, and bank credit applications. The document contains substantive financial data for 2019, including revenue, net profit, equity, and cash flow figures, as well as detailed voting results. The content is comprehensive and includes financial statements and analysis for a full fiscal year, consistent with an Annual Report. The document is not merely an announcement of a report but includes the actual financial data and board resolutions approving these reports. Therefore, it fits the definition of an Annual Report (10-K). FY 2019
2020-04-24 Chinese
2019年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度审计委员会工作报告' which translates to '2019 Annual Audit Committee Work Report'. It details the audit committee's activities, including supervision of external auditors, internal audit guidance, review of financial reports, evaluation of internal controls, and coordination between management and auditors. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, indicating it is a formal audit committee report. The content focuses on audit committee work rather than the full annual report or standalone audit opinion. The length is under 5,000 characters but contains substantive content about audit committee activities, not just an announcement. Therefore, it fits best under Audit Report / Information (AR), which includes audit committee reports and related audit information, excluding full annual reports. FY 2019
2020-04-24 Chinese
关于申请银行综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company's board regarding the application for a comprehensive bank credit facility. It details the proposed credit limits, the purpose of the credit, and the authorization for management to use the credit within the approved limits. There is no financial report, earnings data, or detailed financial statements included. The document is focused on financing activities and credit arrangements, which aligns with updates on company fundraising or capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or a regulatory filing. Confidence is high due to clear content about credit facility application and authorization.
2020-04-24 Chinese
2019年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2019 from a Chinese pharmaceutical company. It details the independent directors' duties, attendance at board and committee meetings, opinions on financial audits, related party transactions, guarantees, senior management appointments, internal controls, and overall evaluation of their role during the year. The content is a detailed report on the independent directors' activities and oversight for the annual period, which is typical of a governance or board-related report. It is not a full annual report (10-K), nor is it a brief announcement or certification. It focuses on the independent directors' duties and opinions, which aligns with Board/Management Information filings. Given the detailed nature and focus on board activities and management oversight, the best classification is Board/Management Information (MANG). The document length (3333 characters) is sufficient for a substantive report but not a full annual report. Confidence is high due to the clear focus on independent directors' annual duties and opinions.
2020-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.